SHP-1 in cell-cycle regulation

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 89-98

  López Ruiz, Pilar ^a   Rodriguez Ubreva, Javier ^b   Cariaga, Ariel Ernesto ^a   Cortes, María Alicia ^a   Colás, Begoña ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cancer; CDK2; Cyclin d; p27; Protein tyrosine phosphatase; PTPN6; SH2 domain

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; PROTEIN P27; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1;

CELL CYCLE REGULATION; CELL PROLIFERATION; CELL TYPE; ENZYME ACTIVITY; HEMATOPOIETIC CELL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR GROWTH;

EID: 79953018682     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011794941154     Document Type: Review

References (104)

1. Collins, I.; Garrett, M.D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol., 2005, 5, 366-373.
2. J. Cyclin C makes an entry into the cell cycle. Dev. Cell., 2004, 6, 607-608.
3. Hochegger, H.; Takeda, S.; Hunt, T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat. Rev. Mol. Cell Biol., 2008, 9, 910-916.
4. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer., 2009, 9, 153-166.
5. Sherr, C.J.; Roberts, J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 1999, 13, 1501-1512.
6. Sherr, C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res., 2000, 60, 3689-3695.
7. Besson, A.; Dowdy, S.F.; Roberts, J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell., 2008, 14, 159-169.
8. Cheng, M.; Olivier, P.; Diehl, J.A.; Fero, M.; Roussel, M.F.; Roberts, J.M.; Sherr, C.J. The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J., 1999, 18, 1571-1583.
9. Park, M.T.; Lee, S.J. Cell cycle and cancer. J. Biochem. Mol. Biol., 2003, 36, 60-65.
10. Taya, Y. RB kinases and RB-binding proteins: new points of view. Trends Biochem. Sci., 1997, 22, 14-17.
11. Deshpande, A.; Sicinski, P.; Hinds, P.W. Cyclins and cdks in development and cancer: a perspective. Oncogene, 2005, 24, 2909-2915.
12. Chu, I.M.; Hengst, L.; Slingerland, J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer, 2008, 8, 253-267.
13. G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 2006, 24, 1770-1783.
14. Pagano, M.; Tam, S.W.; Theodoras, A.M.; Beer-Romero, P.; Del Sal, G.; Chau, V.; Yew, P.R.; Draetta, G.F.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin- dependent kinase inhibitor p27. Science, 1995, 269, 682-685.
15. Hengst, L.; Reed, S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science, 1996, 271, 1861-1864.
16. Slingerland, J.; Pagano, M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell. Physiol., 2000, 183, 10-17.
17. Bloom, J.; Pagano, M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol., 2003, 13, 41-47.
18. Alkarain, A.; Slingerland, J. Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res., 2004, 6, 13-21.
19. Inoue, T.; Kamiyama, J.; Sakai, T. Sp1 and NF-Y synergistically mediate the effect of vitamin D3 in the p27Kip1 gene promoter that lacks vitamin D response elements. J. Biol. Chem., 1999, 274, 32309-32317.
20. Graff, J.R.; Konicek, B.W.; McNulty, A.M.; Wang, Z.; Houck, K.; Allen, S.; Paul, J.D.; Hbaiu, A.; Goode, R.G.; Sandusky, G.E.; Vessella, R.L.; Neubauer, B.L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem., 2000, 275, 24500-24505.
21. Medema, R.H.; Kops, G.J.; Bos, J.L.; Burgering, B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature, 2000, 404, 782-787.
22. Davies, M.A.; Koul, D.; Dhesi, H.; Berman, R.; McDonnell, T.J.; McConkey, D.; Yung, W.K.; Steck, P.A. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res., 1999, 59, 2551-2556.
23. Andersen, J.N.; Jansen, P.G.; Echwald, S.M.; Mortensen, O.H.; Fukada, T.; Del Vecchio, R.; Tonks, N.K.; Møller, N.P. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J., 2004, 18, 8-30.
24. Lorenz, U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol. Rev., 2009, 228, 342-359.
25. Neel, B.G.; Gu, H.; Pao, L. The 'Shp'ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem. Sci., 2003, 28, 284-293.
26. Yi, T.L.; Cleveland, J.L.; Ihle, J.N. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol. Cell. Biol., 1992, 12, 836-846.
27. Plutzky, J.; Neel, B.G.; Rosenberg, R.D.; Eddy, R.L.; Byers, M.G.; Jani-Sait, S.; Shows, T.B. Chromosomal localization of an SH2- containing tyrosine phosphatase (PTPN6). Genomics, 1992, 13, 869-872.
28. Banville, D.; Stocco, R.; Shen, S.H. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics, 1995, 27, 165-173.
29. Jin, Y.J.; Yu, C.L.; Burakoff, S.J. Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure and catalytic activity. J. Biol. Chem., 1999, 274, 28301-28307.
30. Poole, A.W.; Jones, M.L. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the Cterminal tail. Cell. Signal., 2005, 17, 1323-1332.
31. Hof, P.; Pluskey, S.; Dhe-Paganon, S.; Eck, M.J.; Shoelson, S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998, 92, 441-450.
32. Yang, J.; Liu, L.; He, D.; Song, X.; Liang, X.; Zhao, Z.J.; Zhou, G.W. Crystal structure of human protein-tyrosine phosphatase SHP-1. J. Biol. Chem., 2003, 278, 6516-6520.
33. Craggs, G.; Kellie, S. A functional nuclear localization sequence in the C-terminal domain of SHP-1. J. Biol. Chem., 2001, 276, 23719-23725.
34. Sankarshanan, M.; Ma, Z.; Iype, T.; Lorenz, U. Identification of a novel lipid raft-targeting motif in Src homology 2-containing phosphatase 1. J. Immunol., 2007, 179, 483-490.
35. Liu, Y.; Kruhlak, M.J.; Hao, J.J.; Shaw, S. Rapid T cell receptormediated SHP-1 S591 phosphorylation regulates SHP-1 cellular localization and phosphatase activity. J. Leukoc. Biol., 2007, 82, 742-751.
36. Fawcett, V.C.; Lorenz, U. Localization of Src homology 2 domaincontaining phosphatase 1 (SHP-1) to lipid rafts in T lymphocytes: functional implications and a role for the SHP-1 carboxyl terminus. J. Immunol., 2005, 174, 2849-2859.
37. Su, M.W.; Yu, C.L.; Burakoff, S.J.; Jin, Y.J. Targeting Src homology 2 domain-containing tyrosine phosphatase (SHP-1) into lipid rafts inhibits CD3-induced T cell activation. J. Immunol., 2001, 166, 3975-3982.
38. Shultz, L.D.; Schweitzer, P.A.; Rajan, T.V.; Yi, T.; Ihle, J.N.; Matthews, R.J.; Thomas, M.L.; Beier, D.R. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell, 1993, 73, 1445-1454.
39. Zhang, J.; Somani, A.K.; Siminovitch, K.A. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol., 2000, 12, 361-378.
40. Zhang, Q.; Raghunath, P.N.; Vonderheid, E.; Odum, N.; Wasik, M.A. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am. J. Pathol., 2000, 157, 1137-1146.
41. Valencia, A.M.; Oliva, J.L.; Bodega, G.; Chiloeches, A.; Lopez- Ruiz, P.; Prieto, J.C.; Susini, C.; Colás, B. Identification of a protein- tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate. FEBS Lett., 1997, 406, 42-48.
42. Zapata, P.D.; Ropero, R.M.; Valencia, A.M.; Buscail, L.; Lopez, J.I.; Martin-Orozco, R.M.; Prieto, J.C.; Angulo, J.; Susini, C.; Lopez- Ruiz, P.; Colás, B. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J. Clin. Endocrinol. Metab., 2002, 87, 915-926.
43. Keilhack, H.; Muller, M.; Böhmer, S.A.; Frank, C.; Weidner, K.M.; Birchmeier, W.; Ligensa, T.; Berndt, A.; Kosmehl, H.; Gunther, B.; Muller, T.; Birchmeier, C.; Böhmer, F.D. Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1. J. Cell Biol., 2001, 152, 325-334.
44. Tenev, T.; Böhmer, S.A.; Kaufmann, R.; Frese, S.; Bittorf, T.; Beckers, T.; Böhmer, F.D. Perinuclear localization of the proteintyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur. J. Cell Biol., 2000, 79, 261-271.
45. Wu, C.; Guan, Q.; Wang, Y.; Zhao, Z.J.; Zhou, G.W. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J. Cell. Biochem., 2003, 90, 1026-1037.
46. Schnekenburger, J.; Mayerle, J.; Kruger, B.; Buchwalow, I.; Weiss, F.U.; Albrecht, E.; Samoilova, V.E.; Domschke, W.; Lerch, M.M. Protein tyrosine phosphatase κ and SHP-1 are involved in the regulation of cell-cell contacts at adherens junctions in the exocrine pancreas. Gut, 2005, 54, 1445-1455.
47. Duchesne, C.; Charland, S.; Asselin, C.; Nahmias, C.; Rivard, N. Negative regulation of beta-catenin signaling by tyrosine phosphatase SHP-1 in intestinal epithelial cells. J. Biol. Chem., 2003, 278, 14274-14283.
48. Dubois, M.J.; Bergeron, S.; Kim, H.J.; Dombrowski, L.; Perreault, M.; Fournes, B.; Faure, R.; Olivier, M.; Beauchemin, N.; Shulman, G.I.; Siminovitch, K.A.; Kim, J.K.; Marette, A. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat. Med., 2006, 12, 549-556.
49. Aoki, K.; Didomenico, E.; Sims, N.A.; Mukhopadhyay, K.; Neff, L.; Houghton, A.; Amling, M.; Levy, J.B.; Horne, W.C.; Baron, R. The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in mev/mev mutant mice. Bone, 1999, 25, 261-267.
50. Ganesan, L.P.; Fang, H.; Marsh, C.B.; Tridandapani, S. The protein- tyrosine phosphatase SHP-1 associates with the phosphorylated immunoreceptor tyrosine-based activation motif of Fc gamma RIIa to modulate signaling events in myeloid cells. J. Biol. Chem., 2003, 278, 35710-35717.
51. Minoo, P.; Zadeh, M.M.; Rottapel, R.; Lebrun, J.J.; Ali, S. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine- receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood, 2004, 103, 1398-1407.
52. Kanagasundaram, V.; Jaworowski, A.; Byrne, R.; Hamilton, J.A. Separation and characterization of the activated pool of colonystimulating factor 1 receptor forming distinct multimeric complexes with signalling molecules in macrophages. Mol. Cell. Biol., 1999, 19, 4079-4092.
53. Chong, Z.Z.; Maiese, K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol., 2007, 22, 1251-1267.
54. Tenev, T.; Keilhack, H.; Tomic, S.; Stoyanov, B.; Stein-Gerlach, M.; Lammers, R.; Krivtsov, A.V.; Ullrich, A.; Böhmer, F.D. Both SH2 domains are involved in interaction of SHP-1 with the epidermal growth factor receptor but cannot confer receptor-directed activity to SHP-1/SHP-2 chimera. J. Biol. Chem., 1997, 272, 5966-5973.
55. Keilhack, H.; Tenev, T.; Nyakatura, E.; Godovac-Zimmermann, J.; Nielsen, L.; Seedorf, K.; Böhmer, F.D. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. J. Biol. Chem., 1998, 273, 24839-24846.
56. Matsubara, H.; Shibasaki, Y.; Okigaki, M.; Mori, Y.; Masaki, H.; Kosaki, A.; Tsutsumi, Y.; Uchiyama, Y.; Fujiyama, S.; Nose, A.; Iba, O.; Tateishi, E.; Hasegawa, T.; Horiuchi, M.; Nahmias, C.; Iwasaka, T. Effect of angiotensin II type 2 receptor on tyrosine kinase Pyk2 and c-Jun NH2-terminal kinase via SHP-1 tyrosine phosphatase activity: evidence from vascular-targeted transgenic mice of AT2 receptor. Biochem. Biophys. Res. Commun., 2001, 282, 1085-1091.
57. Yu, Z.; Su, L.; Hoglinger, O.; Jaramillo, M.L.; Banville, D.; Shen, S.H. SHP-1 associates with both platelet-derived growth factor receptor and the p85 subunit of phosphatidylinositol 3-kinase. J. Biol. Chem., 1998, 273, 3687-3694.
58. Cuevas, B.; Lu, Y.; Watt, S.; Kumar, R.; Zhang, J.; Siminovitch, K.A.; Mills, G.B. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J. Biol. Chem., 1999, 274, 27583-27589.
59. Nakagami, H.; Cui, T.X.; Iwai, M.; Shiuchi, T.; Takeda-Matsubara, Y.; Wu, L.; Horiuchi, M. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 238-242.
60. Keilhack, H.; Hellman, U.; van Hengel, J.; van Roy, F.; Godovac- Zimmermann, J.; Böhmer, F.D. The protein-tyrosine phosphatase SHP-1 binds to and dephosphorylates p120 catenin. J. Biol. Chem., 2000, 275, 26376-26384.
61. Simoneau, M.; Coulombe, G.; Vandal, G.; Vezina, A.; Rivard, N. SHP-1 inhibits β-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell. Signal., 2010 23, 269-279.
62. Valentino, L.; Pierre, J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol., 2006, 71, 713-721.
63. Bousquet, C.; Delesque, N.; Lopez, F.; Saint-Laurent, N.; Esteve, J.P.; Bedecs, K.; Buscail, L.; Vaysse, N.; Susini, C. sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. J. Biol. Chem., 1998, 273, 7099-7106.
64. Lopez, F.; Ferjoux, G.; Cordelier, P.; Saint-Laurent, N.; Esteve, J.P.; Vaysse, N.; Buscail, L.; Susini, C. Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling. FASEB J., 2001, 15, 2300-2302.
65. Theodoropoulou, M.; Zhang, J.; Laupheimer, S.; Paez-Pereda, M.; Erneux, C.; Florio, T.; Pagotto, U.; Stalla, G.K. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res., 2006, 66, 1576-1582.
66. Su, L.; Zhao, Z.; Bouchard, P.; Banville, D.; Fischer, E.H.; Krebs, E.G.; Shen, S.H. Positive effect of overexpressed protein-tyrosine phosphatase PTP1C on mitogen-activated signaling in 293 cells. J. Biol. Chem., 1996, 271, 10385-10390.
67. Nakata, K.; Suzuki, Y.; Inoue, T.; Ra, C.; Yakura, H.; Mizuno, K. Deficiency of SHP1 leads to sustained and increased ERK activation in mast cells, thereby inhibiting IL-3-dependent proliferation and cell death. Mol. Immunol., 2010, 48, 472-480.
68. Seo, D.W.; Li, H.; Qu, C.K.; Oh, J.; Kim, Y.S.; Diaz, T.; Wei, B.; Han, J.W.; Stetler-Stevenson, W.G. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J. Biol. Chem., 2006, 281, 3711-3721.
69. Pages, P.; Benali, N.; Saint-Laurent, N.; Esteve, J.P.; Schally, A.V.; Tkaczuk, J.; Vaysse, N.; Susini, C.; Buscail, L. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J. Biol. Chem., 1999, 274, 15186-15193.
70. Rodriguez-Ubreva, F.J.; Cariaga-Martinez, A.E.; Cortes, M.A.; Romero-De Pablos, M.; Ropero, S.; Lopez-Ruiz, P.; Colas, B. Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Oncogene, 2010, 29, 345-355.
71. Sebastian, B.; Kakizuka, A.; Hunter, T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 3521-3524.
72. Ram, P.A.; Waxman, D.J. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J. Biol. Chem., 1997, 272, 17694-17702.
73. Caron, D.; Savard, P.E.; Doillon, C.J.; Olivier, M.; Shink, E.; Lussier, J.G.; Faure, R.L. Protein tyrosine phosphatase inhibition induces anti-tumor activity: evidence of Cdk2/p27kip1 and Cdk2/SHP-1 complex formation in human ovarian cancer cells. Cancer Lett., 2008, 262, 265-275.
74. Simoneau, M.; Boulanger, J.; Coulombe, G.; Renaud, M.A.; Duchesne, C.; Rivard, N. Activation of Cdk2 stimulates proteasome- dependent truncation of tyrosine phosphatase SHP-1 in human proliferating intestinal epithelial cells. J. Biol. Chem., 2008, 283, 25544-25556.
75. Liang, J.; Zubovitz, J.; Petrocelli, T.; Kotchetkov, R.; Connor, M.K.; Han, K.; Lee, J.H.; Ciarallo, S.; Catzavelos, C.; Beniston, R.; Franssen, E.; Slingerland, J.M. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med., 2002, 8, 1153-1160.
76. Fujita, N.; Sato, S.; Katayama, K.; Tsuruo, T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem., 2002, 277, 28706-28713.
77. Nakagawa, H.; Mutoh, T.; Kumano, T.; Kuriyama, M. Tyrosine phosphorylation of the catalytic subunit p110 of phosphatidylinositol-3 kinase induced by HMG-CoA reductase inhibitor inhibits its kinase activity in L6 myoblasts. FEBS Lett., 2001, 508, 53-56.
78. Germain, D.; Frank, D.A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res., 2007, 13, 5665-5669.
79. Han, Y.; Amin, H.M.; Franko, B.; Frantz, C.; Shi, X.; Lai, R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood, 2006, 108, 2796-2803.
80. Pandey, M.K.; Sung, B.; Ahn, K.S.; Aggarwal, B.B. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol. Pharmacol., 2009, 75, 525-533.
81. Ahn, K.S.; Sethi, G.; Sung, B.; Goel, A.; Ralhan, R.; Aggarwal, B.B. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res., 2008, 68, 4406-4415.
82. Chen, K.F.; Tai, W.T.; Liu, T.H.; Huang, H.P.; Lin, Y.C.; Shiau, C.W.; Li, P.K.; Chen, P.J.; Cheng, A.L. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res., 2010, 16, 5189-5199.
83. Kannappan, R.; Yadav, V.R.; Aggarwal, B.B. γ-tocotrienol but notγ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J. Biol. Chem., 2010, 285, 33520-33528.
84. Ozawa, T.; Nakata, K.; Mizuno, K.; Yakura, H. Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells. Int. Immunol., 2007, 19, 1049-1061.
85. He, D.; Song, X.; Liu, L.; Burk, D.H.; Zhou, G.W. EGFstimulation activates the nuclear localization signal of SHP-1. J. Cell. Biochem., 2005, 94, 944-953.
86. Bruecher-Encke, B.; Griffin, J.D.; Neel, B.G.; Lorenz, U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia, 2001, 15, 1424-1432.
87. Oka, T.; Yoshino, T.; Hayashi, K.; Ohara, N.; Nakanishi, T.; Yamaai, Y.; Hiraki, A.; Sogawa, C.A.; Kondo, E.; Teramoto, N.; Takahashi, K.; Tsuchiyama, J.; Akagi, T. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am. J. Pathol., 2001, 159, 1495-1505.
88. Chim, C.S.; Wong, A.S.; Kwong, Y.L. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann. Hematol., 2004, 83, 527-532.
89. Oka, T.; Ouchida, M.; Koyama, M.; Ogama, Y.; Takada, S.; Nakatani, Y.; Tanaka, T.; Yoshino, T.; Hayashi, K.; Ohara, N.; Kondo, E.; Takahashi, K.; Tsuchiyama, J.; Tanimoto, M.; Shimizu, K.; Akagi, T. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res., 2002, 62, 6390-6394.
90. Cariaga-Martinez, A.E.; Lorenzati, M.A.; Riera, M.A.; Cubilla, M.A.; De La Rossa, A.; Giorgio, E.M.; Tiscornia, M.M.; Gimenez, E.M.; Rojas, M.E.; Chaneton, B.J.; Rodriguez, D.I.; Zapata, P.D. Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. Adv. Urol., 2009, 723831. [Epub 2009 Apr 12].
91. Yip, S.S.; Crew, A.J.; Gee, J.M.; Hui, R.; Blamey, R.W.; Robertson, J.F.; Nicholson, R.I.; Sutherland, R.L.; Daly, R.J. Upregulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int. J. Cancer, 2000, 88, 363-368.
92. Insabato, L.; Amelio, I.; Quarto, M.; Zannetti, A.; Tolino, F.; de Mauro, G.; Cerchia, L.; Riccio, P.; Baumhoer, D.; Condorelli, G.; Terracciano, L.; de Franciscis, V. Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors. Oncology, 2009, 77, 378-384.
93. Tassidis, H.; Brokken, L.J.; Jirstrom, K.; Ehrnstrom, R.; Ponten, F.; Ulmert, D.; Bjartell, A.; Harkonen, P.; Wingren, A.G. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. Int. J. Cancer., 2010, 126, 2296-2307.
94. Irandoust, M.; van den Berg, T.K.; Kaspers, G.J.; Cloos, J. Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs). Anticancer Agents Med Chem. 2009, 9, 212-220.
95. P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr. Med. Chem., 2009, 16, 706-733.
96. Tsui, H.W.; Hasselblatt, K.; Martin, A.; Mok, S.C.; Tsui, F.W. Molecular mechanisms underlying SHP-1 gene expression. Eur. J. Biochem., 2002, 269, 3057-3064.
97. Ropero, S.; Esteller, M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007, 1, 19-25.
98. Xu, Y.; Banville, D.; Zhao, H.F.; Zhao, X.; Shen, S.H. Transcriptional activity of the SHP-1 gene in MCF7 cells is differentially regulated by binding of NF-Y factor to two distinct CCAATelements. Gene, 2001, 269, 141-153.
99. Koltermann, A.; Liebl, J.; Furst, R.; Ammer, H.; Vollmar, A.M.; Zahler, S. Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. J. Cell. Mol. Med., 2009, 13, 2122-2130.
100. Sandur, S.K.; Pandey, M.K.; Sung, B.; Aggarwal, B.B. 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol. Cancer Res., 2010, 8, 107-118.
101. Kunnumakkara, A.B.; Nair, A.S.; Sung, B.; Pandey, M.K.; Aggarwal, B.B. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer Res., 2009, 7, 118-128.
102. Hampel, K.; Kaufhold, I.; Zacharias, M.; Böhmer, F.D.; Imhof, D. Phosphopeptide ligands of the SHP-1 N-SH2 domain: effects on binding and stimulation of phosphatase activity. ChemMedChem, 2006, 1, 869-877.
103. S.A. Shedding light on immunotherapy for cancer. N. Engl. J. Med., 2004, 350, 1461-1463.
104. Kundu, S.; Fan, K.; Cao, M.; Lindner, D.J.; Zhao, Z.J.; Borden, E.; Yi, T. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J. Immunol., 2010, 184, 6529-6536.